Shake Shack has lowered its Q2 revenue guidance to $415-$420 million from the previous $424-$428 million, citing macroeconomic uncertainty and a tough competitive environment. Same-store sales growth projections were also reduced to 2.5%-3.0% from 3.0%-5.0%, with expected lower profit margins. The stock reacted negatively, dropping 8.10% to a new 52-week low of $54.77, reflecting investor concerns. Analysts maintain a hold rating as the company navigates a challenging market landscape.
AstraZeneca reported updated Phase 3 SERENA-6 trial results showing that camizestrant combined with a CDK4/6 inhibitor significantly improved progression-free survival in hormone receptor-positive, HER2-negative advanced breast cancer. The treatment ...
Clean energy stocks, tracked by the Invesco WilderHill Clean Energy ETF, have surged 130% since the 2026 inauguration despite the Trump administration's rollback of Biden-era clean energy subsidies. The rally is fueled by rising demand for electricit...
Donaldson reported record third-quarter sales of $995.1 million, up 5.8% year-over-year, surpassing analyst expectations. Adjusted earnings per share were $1.06, slightly above estimates, despite a small margin decline due to operational inefficienci...
NASB Financial, Inc. announced a quarterly cash dividend of $0.35 per share, payable on June 26, 2026, to shareholders of record as of June 12, 2026. This dividend reflects NASB's ongoing commitment to returning value to its investors. NASB Financial...
Gilead Sciences announced positive Phase 3 IDEAL study results for Livdelzi (seladelpar) in treating primary biliary cholangitis (PBC). The drug significantly normalized alkaline phosphatase (ALP), a critical liver disease marker, in patients with in...
